Actively Recruiting

Phase Not Applicable
Age: 18Years - 65Years
FEMALE
Healthy Volunteers
NCT03689842

Feasibility Study of Uterine Transplantation From Living Donors in Terms of Efficacy and Safety in Patients With Mayer-Rokitansky-Küster-Hauser Syndrome (MRKH)

Led by Hopital Foch · Updated on 2025-03-07

20

Participants Needed

1

Research Sites

887 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

In France, one in 4500 women is affected by the MayerRokitantskyKüsterHauser (MRKH) syndrome which is characterized by the absence of uterus at birth. Currently, the only solutions for these patients are: * Gestational surrogacy, prohibited in France * Adoption * Resignation Uterine transplantation could become a good alternative. This study is conducted in 10 patients with MRKH type I syndrome, who will be transplanted from a living donor uterus

CONDITIONS

Official Title

Feasibility Study of Uterine Transplantation From Living Donors in Terms of Efficacy and Safety in Patients With Mayer-Rokitansky-Küster-Hauser Syndrome (MRKH)

Who Can Participate

Age: 18Years - 65Years
FEMALE
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Female patients aged between 18 and 38 years
  • Diagnosis of Mayer-Rokitansky-Küster-Hauser Type I Uterine Vaginal Agenesis without renal, cardiac, or bone malformations
  • In a stable relationship with a pregnancy plan and favorable psychological evaluation
  • No history of cancer or blood transfusion
  • Living donor is a related woman without neurological, nephro-urological, infectious, psychiatric, or psychological conditions
  • Living donor has no history of uterine surgery or major abdomino-pelvic pathology
Not Eligible

You will not qualify if you...

  • Recipient with severe sperm issues in the husband (extreme oligo-astheno-spermia or azoospermia)
  • Recipient with history of abdominopelvic surgery except uncomplicated appendectomy or vaginal residue preventing anastomosis
  • Living donor with known thromboembolic risk factors
  • Living donor incompatible with recipient by blood group, rhesus factor, or HLA

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Hopital Foch

Suresnes, France, 92150

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Feasibility Study of Uterine Transplantation From Living Donors in Terms of Efficacy and Safety in Patients With Mayer-Rokitansky-Küster-Hauser Syndrome (MRKH) | DecenTrialz